Although evidence supporting the use of emerging therapies like SGLT2 inhibitors for DKD continues to grow, these agents are associated with side effects such as hyperkalemia and transient renal dysfunction [6]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.